-
公开(公告)号：US20240325311A1
公开(公告)日：2024-10-03
申请号：US18576610
申请日：2022-06-27
发明人： Jin Wook TAK , Ji Won BAEK , Taek Kwan KWON , Ho Taek IM , Yong II KIM
IPC分类号： A61K9/20 , A61K9/00 , A61K31/155 , A61K31/351 , A61K31/4985
CPC分类号： A61K9/2077 , A61K9/0053 , A61K9/2009 , A61K9/2095 , A61K31/155 , A61K31/351 , A61K31/4985
摘要： An oral dosage form in a form of a bi-layer complex tablet is disclosed. The bi-layer oral complex tablet contains colloidal silicon dioxide in an amount of 0.5 to 2% by weight based on a total weight of the first layer. A method for manufacturing the bi-layer oral complex tablet dosage form is also disclosed.
-
公开(公告)号：US12090248B2
公开(公告)日：2024-09-17
申请号：US17311070
申请日：2019-12-06
发明人： Soo Jin Kim , Se Kweon Kim , Chung Leol Shin , Hyo Seung Park , Yong Woo Kim , Back Ho Lee , Jun Young Kim
CPC分类号： A61L27/20 , A61L27/52 , C08B37/0072 , C08J3/14 , C08J3/24 , C08L5/08 , C08J2305/08 , C08L2203/02
摘要： Provided are a crosslinked hyaluronic acid product in the form of powder and a method of preparing the same, and a crosslinked hyaluronic acid hydrogel prepared using the crosslinked hyaluronic acid product in the form of powder, and a method of preparing the same. The crosslinked hyaluronic acid hydrogel according to the present disclosure exhibits excellent rheological properties, and mass production thereof is easy and quality uniformity thereof is excellent.
-
公开(公告)号：US20240239895A1
公开(公告)日：2024-07-18
申请号：US18554236
申请日：2022-04-07
发明人： Darlene Dela Cruz , Shiva Malek , Ehud Segal , Ivana Yen Yen YEN , In Hwan BAE , Kwee Hyun SUH
IPC分类号： C07K16/28 , A61K31/519 , A61K39/00 , A61P35/00
CPC分类号： C07K16/2827 , A61K31/519 , A61P35/00 , A61K2039/505 , A61K2039/545
摘要： A combination therapy comprising a RAF inhibitor and a PD-1 axis inhibitor is provided for the treatment of cancer characterized by a mutated MAPK signaling pathway.
-
4.发明公开公开(公告)号：US20240197834A1
公开(公告)日：2024-06-20
申请号：US18285753
申请日：2022-04-11
发明人： Seon Myeong LEE , Jong Suk LEE , Jung Kuk KIM , Eun Jin PARK
CPC分类号： A61K38/26 , A61K47/6835 , A61P13/12
摘要： Provided are a glucagon derivative and use thereof. The pharmaceutical composition contains a glucagon derivative and a pharmaceutically acceptable excipient, wherein the glucagon derivative is a peptide including an amino acid sequence of the following General Formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-W-L-X27-X28-X29-X30 (General Formula 1, SEQ ID NO: 46). A method for treating chronic renal disease is also disclosed.
-
公开(公告)号：US11925691B2
公开(公告)日：2024-03-12
申请号：US16484290
申请日：2018-02-07
发明人： Su Yeon Park , Dae Jin Kim , Sung Youb Jung , Yong Gyu Jung , Hyun Sik Yun
IPC分类号： A61K47/68 , A61K47/54 , A61K47/60 , C07D225/08
CPC分类号： A61K47/6889 , A61K47/545 , A61K47/60 , A61K47/6803 , C07D225/08
摘要： One aspect of the present invention provides a compound in which a functional group capable of binding to a globulin Fc region or a physiologically active polypeptide is introduced at one end of a non-peptidic polymer and a functional group capable of a click reaction is introduced at the other end; a polypeptide conjugate in which a physiologically active polypeptide binds to one end of the compound; a physiologically active polypeptide conjugate in which a physiologically active polypeptide and an immunoglobulin Fc region bind to both ends thereof by using the compound as a linker; and methods for preparing the same compound, polypeptide conjugate, and physiologically active polypeptide conjugate.
-
公开(公告)号：US20240024426A1
公开(公告)日：2024-01-25
申请号：US18041151
申请日：2021-08-17
发明人： Seungjae BAEK , Jaeduk CHOI , Wonjung SHIN , Jung Kuk KIM , Jong Suk LEE , Jae Hyuk CHOI , Euh Lim OH
CPC分类号： A61K38/26 , A61K47/6811 , A61P9/12 , A61K47/6889
摘要： A method for lowering blood pressure is disclosed. The method includes administering a pharmaceutical composition to a subject in need thereof, wherein the composition contains a pharmaceutically acceptable excipient; and a peptide having an amino acid sequence of any one of SEQ ID NOS: 1 to 102. The peptide is in a form of a long-acting conjugate.
-
公开(公告)号：US20230381281A1
公开(公告)日：2023-11-30
申请号：US18031940
申请日：2021-10-18
发明人： Eun Jung KIM , Jae Hyuk CHOl , Jung Kuk KIM , Jeong A KIM , Euh Lim OH
摘要： Provided is a pharmaceutical composition for preventing or treating lupus-associated disease, including a glucagon/GLP-1/GIP triple agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof.
-
公开(公告)号：US20230381279A1
公开(公告)日：2023-11-30
申请号：US18031781
申请日：2021-10-18
发明人： Eun Jung KIM , Jae Hyuk CHOI , Jeong A KIM , Nyeong Sang YOO , Hyeon Joo IM
CPC分类号： A61K38/22 , A61P37/06 , A61K47/6811 , A61K47/60
摘要： Provided is a pharmaceutical composition for preventing or treating lupus-associated disease, including a GIP derivative, a pharmaceutically acceptable salt or solvate thereof, or a long-acting conjugate thereof.
-
公开(公告)号：US20230348550A1
公开(公告)日：2023-11-02
申请号：US18349656
申请日：2023-07-10
发明人： Euh Lim OH , Sang Yun KIM , Yong Ho HEO , Jin Young KIM , Cho Rong PARK , Jun Sub PARK , Hyun Soo RYU
CPC分类号： C07K14/55 , G01N33/6869
摘要： Modifications to interleukin-2 alpha receptors are disclosed. Interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors are disclosed.
-
10.发明公开公开(公告)号：US20230302148A1
公开(公告)日：2023-09-28
申请号：US18040869
申请日：2021-08-13
发明人： Seungjae BAEK , Jaeduk CHOI , Wonjung SHIN , Jung Kuk KIM
CPC分类号： A61K47/6811 , A61K38/26 , A61K9/0021 , A61K47/60 , A61P1/16
摘要： Provided are a pharmaceutical composition including a long-acting conjugate of a triple agonist as an active ingredient and a method of treating obesity and/or a non-alcoholic fatty liver disease using the same. The pharmaceutical composition including the long-acting conjugate of the triple agonist of the present invention may be stably applied to treatment of obesity and/or a non-alcoholic fatty liver disease without side effects according to therapeutic effects on obesity and/or the non-alcoholic fatty liver disease.
-
-
-
-
-
-
-
-
-
搜索结果
358 条记录 (耗时 0.037 秒)
